The atypical antipsychotics olanzapine and quetiapine, but not haloperidol, reduce ACTH and cortisol secretion in healthy subjects

Increased activity of the hypothalamic-pituitary-adrenal (HPA) axis is an important aspect of the pathophysiology of major depression and schizophrenia. Despite the usefulness of atypical antipsychotics in the treatment of depression and their positive influence on cognitive functioning possibly rel...

Full description

Saved in:
Bibliographic Details
Published inPsychopharmacologia Vol. 185; no. 1; pp. 11 - 18
Main Authors Cohrs, Stefan, Röher, Cornelia, Jordan, Wolfgang, Meier, Andreas, Huether, Gerald, Wuttke, Wolfgang, Rüther, Eckart, Rodenbeck, Andrea
Format Journal Article
LanguageEnglish
Published Berlin Springer 01.03.2006
Springer Nature B.V
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Increased activity of the hypothalamic-pituitary-adrenal (HPA) axis is an important aspect of the pathophysiology of major depression and schizophrenia. Despite the usefulness of atypical antipsychotics in the treatment of depression and their positive influence on cognitive functioning possibly related to their impact on cortisol, little is known about their effect on HPA axis function. Therefore, this double-blind, placebo-controlled, randomized cross-over study investigated the influence of the atypical antipsychotics quetiapine and olanzapine in comparison with haloperidol and placebo on plasma adrenocorticotropic hormone (ACTH), cortisol, and prolactin levels. Eleven healthy male volunteers were studied during four sessions one week apart, orally receiving placebo, quetiapine (50 mg), olanzapine (5 mg), or haloperidol (3 mg). Blood samples were taken at hourly intervals from 0900 until 1700 hours. For ACTH, cortisol, and prolactin a significant effect of treatment condition (p < or = 0.005; p < or = 0.035; p < or = 0.0001, respectively) for area under the curve (AUC) was found. In comparison to placebo, quetiapine and olanzapine significantly reduced ACTH (p < or = 0.002; p < or = 0.05, respectively) and cortisol (p < or = 0.005; p < or = 0.03, respectively). No effect of haloperidol on AUC of ACTH or cortisol levels was observed. In comparison with placebo, haloperidol (p < or = 0.0001) and olanzapine (p < or = 0.0001) elevated AUC of prolactin plasma levels, whereas no significant effect was observed for quetiapine as a main effect of treatment condition. The atypical antipsychotics' strong influence on HPA-function with pronounced ACTH and cortisol lowering is possibly related to the atypicals' blockade of serotonergic receptors, but blockade of adrenergic or histaminergic receptors may play a role as well. The observed HPA-axis down-regulation may be clinically important for the atypicals' effects on depressive symptomatology and cognitive functioning.
AbstractList Increased activity of the hypothalamic-pituitary-adrenal (HPA) axis is an important aspect of the pathophysiology of major depression and schizophrenia. Despite the usefulness of atypical antipsychotics in the treatment of depression and their positive influence on cognitive functioning possibly related to their impact on cortisol, little is known about their effect on HPA axis function. Therefore, this double-blind, placebo-controlled, randomized cross-over study investigated the influence of the atypical antipsychotics quetiapine and olanzapine in comparison with haloperidol and placebo on plasma adrenocorticotropic hormone (ACTH), cortisol, and prolactin levels. Eleven healthy male volunteers were studied during four sessions one week apart, orally receiving placebo, quetiapine (50 mg), olanzapine (5 mg), or haloperidol (3 mg). Blood samples were taken at hourly intervals from 0900 until 1700 hours. For ACTH, cortisol, and prolactin a significant effect of treatment condition (p < or = 0.005; p < or = 0.035; p < or = 0.0001, respectively) for area under the curve (AUC) was found. In comparison to placebo, quetiapine and olanzapine significantly reduced ACTH (p < or = 0.002; p < or = 0.05, respectively) and cortisol (p < or = 0.005; p < or = 0.03, respectively). No effect of haloperidol on AUC of ACTH or cortisol levels was observed. In comparison with placebo, haloperidol (p < or = 0.0001) and olanzapine (p < or = 0.0001) elevated AUC of prolactin plasma levels, whereas no significant effect was observed for quetiapine as a main effect of treatment condition. The atypical antipsychotics' strong influence on HPA-function with pronounced ACTH and cortisol lowering is possibly related to the atypicals' blockade of serotonergic receptors, but blockade of adrenergic or histaminergic receptors may play a role as well. The observed HPA-axis down-regulation may be clinically important for the atypicals' effects on depressive symptomatology and cognitive functioning.
Increased activity of the hypothalamic-pituitary-adrenal (HPA) axis is an important aspect of the pathophysiology of major depression and schizophrenia. Despite the usefulness of atypical antipsychotics in the treatment of depression and their positive influence on cognitive functioning possibly related to their impact on cortisol, little is known about their effect on HPA axis function.RATIONALEIncreased activity of the hypothalamic-pituitary-adrenal (HPA) axis is an important aspect of the pathophysiology of major depression and schizophrenia. Despite the usefulness of atypical antipsychotics in the treatment of depression and their positive influence on cognitive functioning possibly related to their impact on cortisol, little is known about their effect on HPA axis function.Therefore, this double-blind, placebo-controlled, randomized cross-over study investigated the influence of the atypical antipsychotics quetiapine and olanzapine in comparison with haloperidol and placebo on plasma adrenocorticotropic hormone (ACTH), cortisol, and prolactin levels. Eleven healthy male volunteers were studied during four sessions one week apart, orally receiving placebo, quetiapine (50 mg), olanzapine (5 mg), or haloperidol (3 mg). Blood samples were taken at hourly intervals from 0900 until 1700 hours. For ACTH, cortisol, and prolactin a significant effect of treatment condition (p < or = 0.005; p < or = 0.035; p < or = 0.0001, respectively) for area under the curve (AUC) was found. In comparison to placebo, quetiapine and olanzapine significantly reduced ACTH (p < or = 0.002; p < or = 0.05, respectively) and cortisol (p < or = 0.005; p < or = 0.03, respectively). No effect of haloperidol on AUC of ACTH or cortisol levels was observed. In comparison with placebo, haloperidol (p < or = 0.0001) and olanzapine (p < or = 0.0001) elevated AUC of prolactin plasma levels, whereas no significant effect was observed for quetiapine as a main effect of treatment condition. The atypical antipsychotics' strong influence on HPA-function with pronounced ACTH and cortisol lowering is possibly related to the atypicals' blockade of serotonergic receptors, but blockade of adrenergic or histaminergic receptors may play a role as well. The observed HPA-axis down-regulation may be clinically important for the atypicals' effects on depressive symptomatology and cognitive functioning.OBJECTIVETherefore, this double-blind, placebo-controlled, randomized cross-over study investigated the influence of the atypical antipsychotics quetiapine and olanzapine in comparison with haloperidol and placebo on plasma adrenocorticotropic hormone (ACTH), cortisol, and prolactin levels. Eleven healthy male volunteers were studied during four sessions one week apart, orally receiving placebo, quetiapine (50 mg), olanzapine (5 mg), or haloperidol (3 mg). Blood samples were taken at hourly intervals from 0900 until 1700 hours. For ACTH, cortisol, and prolactin a significant effect of treatment condition (p < or = 0.005; p < or = 0.035; p < or = 0.0001, respectively) for area under the curve (AUC) was found. In comparison to placebo, quetiapine and olanzapine significantly reduced ACTH (p < or = 0.002; p < or = 0.05, respectively) and cortisol (p < or = 0.005; p < or = 0.03, respectively). No effect of haloperidol on AUC of ACTH or cortisol levels was observed. In comparison with placebo, haloperidol (p < or = 0.0001) and olanzapine (p < or = 0.0001) elevated AUC of prolactin plasma levels, whereas no significant effect was observed for quetiapine as a main effect of treatment condition. The atypical antipsychotics' strong influence on HPA-function with pronounced ACTH and cortisol lowering is possibly related to the atypicals' blockade of serotonergic receptors, but blockade of adrenergic or histaminergic receptors may play a role as well. The observed HPA-axis down-regulation may be clinically important for the atypicals' effects on depressive symptomatology and cognitive functioning.
Rationale: Increased activity of the hypothalamic-pituitary-adrenal (HPA) axis is an important aspect of the pathophysiology of major depression and schizophrenia. Despite the usefulness of atypical antipsychotics in the treatment of depression and their positive influence on cognitive functioning possibly related to their impact on cortisol, little is known about their effect on HPA axis function. Objective: Therefore, this double-blind, placebo-controlled, randomized cross-over study investigated the influence of the atypical antipsychotics quetiapine and olanzapine in comparison with haloperidol and placebo on plasma adrenocorticotropic hormone (ACTH), cortisol, and prolactin levels. Eleven healthy male volunteers were studied during four sessions one week apart, orally receiving placebo, quetiapine (50 mg), olanzapine (5 mg), or haloperidol (3 mg). Blood samples were taken at hourly intervals from 0900 until 1700 hours. For ACTH, cortisol, and prolactin a significant effect of treatment condition (p less than or equal to 0.005; p less than or equal to 0.035; p less than or equal to 0.0001, respectively) for area under the curve (AUC) was found. In comparison to placebo, quetiapine and olanzapine significantly reduced ACTH (p less than or equal to 0.002; p less than or equal to 0.05, respectively) and cortisol (p less than or equal to 0.005; p less than or equal to 0.03, respectively). No effect of haloperidol on AUC of ACTH or cortisol levels was observed. In comparison with placebo, haloperidol (p less than or equal to 0.0001) and olanzapine (p less than or equal to 0.0001) elevated AUC of prolactin plasma levels, whereas no significant effect was observed for quetiapine as a main effect of treatment condition. The atypical antipsychotics' strong influence on HPA-function with pronounced ACTH and cortisol lowering is possibly related to the atypicals' blockade of serotonergic receptors, but blockade of adrenergic or histaminergic receptors may play a role as well. The observed HPA-axis down-regulation may be clinically important for the atypicals' effects on depressive symptomatology and cognitive functioning.
Increased activity of the hypothalamic-pituitary-adrenal (HPA) axis is an important aspect of the pathophysiology of major depression and schizophrenia. Despite the usefulness of atypical antipsychotics in the treatment of depression and their positive influence on cognitive functioning possibly related to their impact on cortisol, little is known about their effect on HPA axis function. Therefore, this double-blind, placebo-controlled, randomized cross-over study investigated the influence of the atypical antipsychotics quetiapine and olanzapine in comparison with haloperidol and placebo on plasma adrenocorticotropic hormone (ACTH), cortisol, and prolactin levels. Eleven healthy male volunteers were studied during four sessions one week apart, orally receiving placebo, quetiapine (50 mg), olanzapine (5 mg), or haloperidol (3 mg). Blood samples were taken at hourly intervals from 0900 until 1700 hours. For ACTH, cortisol, and prolactin a significant effect of treatment condition (p < or = 0.005; p < or = 0.035; p < or = 0.0001, respectively) for area under the curve (AUC) was found. In comparison to placebo, quetiapine and olanzapine significantly reduced ACTH (p < or = 0.002; p < or = 0.05, respectively) and cortisol (p < or = 0.005; p < or = 0.03, respectively). No effect of haloperidol on AUC of ACTH or cortisol levels was observed. In comparison with placebo, haloperidol (p < or = 0.0001) and olanzapine (p < or = 0.0001) elevated AUC of prolactin plasma levels, whereas no significant effect was observed for quetiapine as a main effect of treatment condition. The atypical antipsychotics' strong influence on HPA-function with pronounced ACTH and cortisol lowering is possibly related to the atypicals' blockade of serotonergic receptors, but blockade of adrenergic or histaminergic receptors may play a role as well. The observed HPA-axis down-regulation may be clinically important for the atypicals' effects on depressive symptomatology and cognitive functioning.
Author Wuttke, Wolfgang
Huether, Gerald
Meier, Andreas
Jordan, Wolfgang
Röher, Cornelia
Cohrs, Stefan
Rüther, Eckart
Rodenbeck, Andrea
Author_xml – sequence: 1
  givenname: Stefan
  surname: Cohrs
  fullname: Cohrs, Stefan
– sequence: 2
  givenname: Cornelia
  surname: Röher
  fullname: Röher, Cornelia
– sequence: 3
  givenname: Wolfgang
  surname: Jordan
  fullname: Jordan, Wolfgang
– sequence: 4
  givenname: Andreas
  surname: Meier
  fullname: Meier, Andreas
– sequence: 5
  givenname: Gerald
  surname: Huether
  fullname: Huether, Gerald
– sequence: 6
  givenname: Wolfgang
  surname: Wuttke
  fullname: Wuttke, Wolfgang
– sequence: 7
  givenname: Eckart
  surname: Rüther
  fullname: Rüther, Eckart
– sequence: 8
  givenname: Andrea
  surname: Rodenbeck
  fullname: Rodenbeck, Andrea
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17577386$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/16432682$$D View this record in MEDLINE/PubMed
BookMark eNqF0k9rFDEYBvAgFbutfgAvEgQ9dfRNMvkzx7K0Vih4Wc8hk8myWWaTMclA16Of3Gx3pdCDzSUEfk_g4X0v0FmIwSH0nsAXAiC_ZgBKWAPAG6Cyax5eoQVpGW0oSHqGFgCMNYxwdY4uct5CPa1q36BzIqoSii7Qn9XGYVP2k7dmxCYUP-W93cTibcZxNOG3mXyoJAz41-yKf3xe4X4uOMSCN2aMk0t-iOMVTm6YrcPXy9XdY8DGVHyOI87OppqNAfuAN86MZbPHee63zpb8Fr1emzG7d6f7Ev28vVkt75r7H9--L6_vG9sSVRrihO3kerCqlZ2tRSwfuqHrLXfOkN4xkJIDl1T0sldMGQPGMiPalruedj27RJ-P_04p1iq56J3P1o21pItz1kIKpbhUL0IKAiTj7EVIOqpaLqHCj8_gNs4p1LaaEtUJ6MThtw8nNPc7N-gp-Z1Je_1vWBV8OgGT67TWyQTr85OTXEqmRHXk6GyKOSe3fiKgD4ujj4uj6-Low-Loh5qRzzLWF3MYWUnGj_9J_gWa-8go
CODEN PSYPAG
CitedBy_id crossref_primary_10_1155_2016_1942828
crossref_primary_10_3389_fendo_2020_00195
crossref_primary_10_3389_fpsyt_2018_00574
crossref_primary_10_1111_j_1749_6632_2009_04978_x
crossref_primary_10_4103_ejpsy_ejpsy_26_21
crossref_primary_10_1016_j_pnpbp_2006_10_007
crossref_primary_10_1016_j_bbr_2019_112305
crossref_primary_10_1007_s11481_019_09857_y
crossref_primary_10_1016_j_psyneuen_2015_10_014
crossref_primary_10_1016_j_schres_2019_06_023
crossref_primary_10_2512_jspm_8_566
crossref_primary_10_1016_j_neubiorev_2016_05_027
crossref_primary_10_1016_j_pnpbp_2010_10_023
crossref_primary_10_1080_08923973_2022_2037628
crossref_primary_10_3390_ijms23020908
crossref_primary_10_1017_S0954579411000289
crossref_primary_10_3389_fpsyt_2018_00501
crossref_primary_10_1016_j_ejphar_2020_172978
crossref_primary_10_3389_fpsyt_2019_00834
crossref_primary_10_1016_j_psyneuen_2012_12_025
crossref_primary_10_1038_sj_npp_1301395
crossref_primary_10_1016_j_pnpbp_2020_110162
crossref_primary_10_1097_JCP_0b013e31829e8333
crossref_primary_10_1002_14651858_CD006995_pub2
crossref_primary_10_3390_jcm10215204
crossref_primary_10_1016_j_psychres_2022_114762
crossref_primary_10_1016_j_ejphar_2008_06_105
crossref_primary_10_1016_j_schres_2007_01_022
crossref_primary_10_1016_j_brainres_2013_06_034
crossref_primary_10_1080_15622975_2018_1433878
crossref_primary_10_1016_j_nbd_2010_04_017
crossref_primary_10_1016_j_psyneuen_2011_08_013
crossref_primary_10_1177_0269881108097715
crossref_primary_10_30773_pi_2020_0269
crossref_primary_10_1016_j_psyneuen_2016_11_036
crossref_primary_10_1016_j_schres_2015_01_010
crossref_primary_10_1146_annurev_clinpsy_4_022007_141248
crossref_primary_10_1590_1516_4446_2014_1634
crossref_primary_10_1016_j_psyneuen_2018_06_007
crossref_primary_10_1517_13543784_2013_782392
crossref_primary_10_3389_fphys_2021_674550
crossref_primary_10_1517_14656566_8_9_1211
crossref_primary_10_1016_j_pscychresns_2011_11_008
crossref_primary_10_1097_JCP_0b013e31814f4d82
crossref_primary_10_1016_j_jand_2021_07_016
crossref_primary_10_1016_j_npep_2008_06_002
crossref_primary_10_3928_00485713_20090625_02
crossref_primary_10_3389_fcell_2022_880544
crossref_primary_10_1016_j_prp_2013_09_010
crossref_primary_10_1007_s11102_008_0114_6
crossref_primary_10_3390_ph16081097
crossref_primary_10_1016_j_psyneuen_2008_11_008
crossref_primary_10_1016_j_bionps_2020_100011
crossref_primary_10_3389_fnut_2022_943998
crossref_primary_10_1586_14737175_7_7_841
crossref_primary_10_1016_j_schres_2016_03_039
crossref_primary_10_1016_j_bionps_2024_100098
crossref_primary_10_1016_j_jpsychires_2014_01_013
crossref_primary_10_1016_j_psychres_2013_12_016
crossref_primary_10_1016_j_neuropharm_2011_07_001
crossref_primary_10_1159_000437437
crossref_primary_10_1016_j_psyneuen_2019_03_014
crossref_primary_10_1016_j_euroneuro_2014_10_005
crossref_primary_10_2174_1570159X21666230322145049
crossref_primary_10_1016_j_neubiorev_2017_12_012
crossref_primary_10_2147_NDT_S306458
crossref_primary_10_1017_S003329172300380X
crossref_primary_10_1080_10253890_2016_1193146
crossref_primary_10_1007_s12031_015_0625_3
crossref_primary_10_1016_j_neubiorev_2016_12_013
crossref_primary_10_1111_bcpt_13323
crossref_primary_10_1016_j_schres_2009_05_008
crossref_primary_10_1142_S0219635214500253
crossref_primary_10_1007_s00213_019_05442_6
crossref_primary_10_1016_j_psyneuen_2008_09_004
crossref_primary_10_1016_j_heliyon_2023_e21173
crossref_primary_10_1016_j_jpsychires_2016_06_014
crossref_primary_10_1097_JCP_0b013e31819b95fc
crossref_primary_10_1080_14789450_2017_1375857
crossref_primary_10_1155_2020_9124520
crossref_primary_10_1111_j_1365_2788_2012_01557_x
crossref_primary_10_1016_j_psyneuen_2016_01_021
crossref_primary_10_1038_tp_2017_94
crossref_primary_10_1016_j_jpsychires_2014_02_022
crossref_primary_10_1097_YIC_0b013e32801182e6
crossref_primary_10_1016_j_psyneuen_2012_06_002
crossref_primary_10_1016_j_schres_2009_10_005
crossref_primary_10_1016_j_pnpbp_2008_09_009
crossref_primary_10_1016_j_schres_2017_04_035
crossref_primary_10_3389_fpsyt_2019_00974
crossref_primary_10_1016_j_biopsycho_2018_08_016
crossref_primary_10_4158_EP12415_CR
crossref_primary_10_1177_1359786810385491
crossref_primary_10_1517_13543784_2010_515586
crossref_primary_10_1124_jpet_113_205864
crossref_primary_10_5937_mp69_17304
crossref_primary_10_1111_j_1365_2826_2006_01516_x
crossref_primary_10_15406_jpcpy_2015_02_00068
crossref_primary_10_1016_j_jad_2020_07_071
crossref_primary_10_1016_j_pnpbp_2010_05_021
crossref_primary_10_1111_j_1601_5215_2008_00340_x
crossref_primary_10_1177_0269881109103090
crossref_primary_10_1016_j_schres_2009_08_013
crossref_primary_10_3390_ph13100322
crossref_primary_10_1186_s40360_017_0171_4
crossref_primary_10_1586_ern_09_52
crossref_primary_10_1007_s00213_006_0452_x
crossref_primary_10_1002_wps_20144
crossref_primary_10_1016_j_psyneuen_2014_07_013
crossref_primary_10_1111_pcn_12093
Cites_doi 10.1023/A:1009986822146
10.1007/BF02245012
10.1016/S0920-9964(01)00268-7
10.1001/archpsyc.1978.01770250110011
10.1093/schbul/20.2.327
10.1001/archpsyc.1976.01770030003001
10.1176/appi.ajp.158.1.131
10.1001/archpsyc.60.11.1079
10.4088/JCP.v65n0109
10.1007/BF00427446
10.1007/BF00442554
10.1016/0024-3205(86)90656-9
10.1016/S0893-133X(00)00159-7
10.1007/BF00735811
10.1016/0165-1781(91)90013-F
10.1097/00004714-199604000-00008
10.1016/S0306-4530(99)00029-3
10.1007/BF00432027
10.1007/s00213-002-1356-z
10.1001/archpsyc.57.6.553
10.1111/j.1600-0404.1993.tb04075.x
10.1016/S0024-3205(00)00911-5
10.1176/appi.ajp.159.1.133
10.1176/appi.books.9798894550442.lg05
10.1517/14656566.3.10.1381
10.1210/jcem-41-5-981
10.1016/S0920-9964(01)00367-X
10.1016/0278-5846(85)90082-X
10.1016/0278-5846(95)00105-5
10.1007/BF02246165
10.1111/j.1365-2125.1995.tb04403.x
10.1097/00004714-200112000-00006
10.1007/BF00546704
10.1007/BF02244242
10.1016/S0278-5846(98)00064-5
10.1016/S0006-3223(00)01052-0
10.1139/y00-098
10.2165/00023210-200317110-00003
10.1111/j.1365-2265.1975.tb01526.x
10.1038/npp.1994.1
10.1097/00005053-198208000-00004
10.1097/00006842-199909000-00011
10.1001/archpsyc.57.3.249
10.3109/15622970209150617
10.1192/bjp.182.3.199
10.1055/s-2007-979503
10.1016/0022-3956(94)90004-3
10.1016/S0006-3223(03)00473-6
10.1016/S0924-977X(99)00017-6
10.1016/S0022-3956(01)00018-8
10.1016/0028-3908(84)90078-9
10.1007/s00213-002-1057-7
10.1176/appi.ajp.159.6.1018
10.1016/S0924-977X(99)00040-1
10.1016/0306-4530(86)90008-9
10.1055/s-2007-979502
10.1111/j.1365-2265.1983.tb02986.x
10.1038/266639a0
10.1176/appi.ajp.159.9.1608
ContentType Journal Article
Copyright 2006 INIST-CNRS
Springer-Verlag 2006
Copyright_xml – notice: 2006 INIST-CNRS
– notice: Springer-Verlag 2006
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7QG
7QR
7RV
7TK
7X7
7XB
88E
88G
8AO
8FD
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FR3
FYUFA
GHDGH
GNUQQ
K9.
KB0
M0S
M1P
M2M
NAPCQ
P64
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
PSYQQ
Q9U
7X8
DOI 10.1007/s00213-005-0279-x
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Animal Behavior Abstracts
Chemoreception Abstracts
Nursing & Allied Health Database
Neurosciences Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Psychology Database (Alumni)
ProQuest Pharma Collection
Technology Research Database
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One
ProQuest Central Korea
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
ProQuest Health & Medical Collection
Medical Database
Psychology Database
Nursing & Allied Health Premium
Biotechnology and BioEngineering Abstracts
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest One Psychology
ProQuest Central Basic
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest One Psychology
ProQuest Central Student
Technology Research Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Pharma Collection
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
Chemoreception Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Central Basic
ProQuest One Academic Eastern Edition
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Psychology Journals (Alumni)
Neurosciences Abstracts
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest Psychology Journals
ProQuest One Academic UKI Edition
Animal Behavior Abstracts
ProQuest Nursing & Allied Health Source (Alumni)
Engineering Research Database
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
Neurosciences Abstracts
ProQuest One Psychology
Neurosciences Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central (New)
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Pharmacy, Therapeutics, & Pharmacology
EISSN 1432-2072
EndPage 18
ExternalDocumentID 993072191
16432682
17577386
10_1007_s00213_005_0279_x
Genre Randomized Controlled Trial
Journal Article
Comparative Study
GroupedDBID .55
3SX
40D
40E
95.
95~
AAYXX
ABMNI
AGWIL
ALMA_UNASSIGNED_HOLDINGS
CITATION
KOW
N2Q
R9-
RHV
SBY
SOJ
X7M
~EX
-4W
-BR
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7QG
7QR
7RV
7TK
7X7
7XB
88E
8AO
8FD
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FR3
FYUFA
GNUQQ
K9.
M1P
M2M
NAPCQ
P64
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
PSYQQ
Q9U
7X8
ID FETCH-LOGICAL-c418t-1e6c97fdc8479c048c5d9d9bc5eea1be3077505726b7b838aa0ac3a6445eb29b3
IEDL.DBID 7X7
ISSN 0033-3158
IngestDate Fri Jul 11 11:56:40 EDT 2025
Thu Jul 10 18:14:49 EDT 2025
Fri Jul 11 08:27:58 EDT 2025
Sun Aug 17 23:55:40 EDT 2025
Sat Sep 28 07:44:48 EDT 2024
Tue Sep 20 18:53:38 EDT 2022
Thu Apr 24 22:59:31 EDT 2025
Tue Jul 01 00:40:02 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Atypical antipsychotic
Olanzapine
Neuroleptic
Psychotropic
Serotonine receptor
Haloperidol
Hydrocortisone
Glucocorticoid
Dibenzothiazepine derivatives
Quetiapine
Human
Corticosteroid
Healthy subject
Steroid hormone
Secretion
Dopamine antagonist
Serotonin antagonist
Hypnotic
Butyrophenone derivatives
Thienobenzodiazepine derivatives
Chemotherapy
D2 Dopamine receptor
Adrenocorticotropic hormone
Tranquillizer
Adenohypophyseal hormone
Adrenal hormone
Language English
License http://www.springer.com/tdm
CC BY 4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c418t-1e6c97fdc8479c048c5d9d9bc5eea1be3077505726b7b838aa0ac3a6445eb29b3
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 14
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
PMID 16432682
PQID 218960963
PQPubID 23462
PageCount 8
ParticipantIDs proquest_miscellaneous_67688578
proquest_miscellaneous_20607353
proquest_miscellaneous_19284570
proquest_journals_218960963
pubmed_primary_16432682
pascalfrancis_primary_17577386
crossref_primary_10_1007_s00213_005_0279_x
crossref_citationtrail_10_1007_s00213_005_0279_x
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2006-03-01
PublicationDateYYYYMMDD 2006-03-01
PublicationDate_xml – month: 03
  year: 2006
  text: 2006-03-01
  day: 01
PublicationDecade 2000
PublicationPlace Berlin
PublicationPlace_xml – name: Berlin
– name: Germany
– name: Heidelberg
PublicationTitle Psychopharmacologia
PublicationTitleAlternate Psychopharmacology (Berl)
PublicationYear 2006
Publisher Springer
Springer Nature B.V
Publisher_xml – name: Springer
– name: Springer Nature B.V
References H Wetzel (279_CR66) 1994; 28
DI Velligan (279_CR61) 2002; 53
S Damluji al (279_CR3) 1993; 7
CS Wilcox (279_CR69) 1975; 4
ES Brown (279_CR15) 2004; 55
B Allolio (279_CR6) 1987; 16
RT Rubin (279_CR50) 1976; 47
HY Meltzer (279_CR42) 1976; 33
F Holsboer (279_CR29) 2000; 23
J Volavka (279_CR62) 2004; 65
AC Altamura (279_CR7) 1999; 10
M Markianos (279_CR39) 1999; 9
C Barbieri (279_CR10) 1984; 26
Y Shirayama (279_CR56) 2002; 58
DJ Walder (279_CR64) 2000; 48
EJ Marco (279_CR38) 2002; 3
M Alexiadis (279_CR4) 2002; 159
J Tuomisto (279_CR59) 1985; 37
S Cohrs (279_CR17) 2004; 174
R Collu (279_CR18) 1975; 41
C Schule (279_CR52) 2003; 166
D Jezova Repcekova (279_CR31) 1979; 17
M Harrow (279_CR26) 1994; 20
JP Seibyl (279_CR54) 1991; 38
G Laakmann (279_CR36) 1999; 24
JR Calabrese (279_CR16) 2004
M Mauri (279_CR40) 1993; 87
HY Meltzer (279_CR41) 1989; 99
RL Borison (279_CR13) 1996; 16
E Richelson (279_CR49) 2000; 68
SC Schulz (279_CR2) 2002; 63
RC Shelton (279_CR55) 2001; 158
PH Gruen (279_CR24) 1978; 35
RM Bilder (279_CR12) 2002; 159
MM Murburg (279_CR45) 1993; 77
279_CR71
G Laakmann (279_CR34) 1984; 84
A Wieck (279_CR68) 2003; 182
H Wetzel (279_CR67) 1995; 119
J Hatzimanolis (279_CR27) 1998; 22
JI Nurnberger Jr (279_CR47) 1984; 84
C Bahr von (279_CR63) 1991; 103
CB Nemeroff (279_CR46) 1997; 58
TE Seeman (279_CR53) 1997; 82
P Koning de (279_CR20) 1995; 39
MM Murburg (279_CR44) 1986; 39
A Breier (279_CR14) 1994; 10
FE Scheepers (279_CR51) 2001; 21
S Kapur (279_CR33) 2000; 57
AM Ghadirian (279_CR22) 1982; 170
T Baptista (279_CR9) 1997; 30
M Hornig (279_CR30) 2003
G Langer (279_CR37) 1977; 266
A Weizman (279_CR65) 1985; 9
JK Belanoff (279_CR11) 2001; 35
T Baptista (279_CR8) 1997; 30
N Sonino (279_CR57) 2000; 3
OM Wolkowitz (279_CR70) 1999; 61
SE Purdon (279_CR48) 2000; 57
HJ Möller (279_CR43) 2003; 17
PJ Goodnick (279_CR23) 2002; 3
J Hennig (279_CR28) 1995; 19
MB Hamner (279_CR25) 1996; 32
G Laakmann (279_CR35) 1986; 11
M Tohen (279_CR58) 2003; 60
B Allolio (279_CR5) 1983; 19
RS Kahn (279_CR32) 1993; 112
P Turrone (279_CR60) 2002; 159
V Contesse (279_CR19) 2000; 78
W Abi Saab (279_CR1) 2002; 162
RW Fuller (279_CR21) 1984; 23
6124580 - J Nerv Ment Dis. 1982 Aug;170(8):463-7
193037 - Nature. 1977 Apr 14;266(5603):639-40
12562145 - J Clin Psychiatry. 2002;63 Suppl 13:32-8
8927658 - Psychopharmacol Bull. 1996;32(1):107-10
10711911 - Arch Gen Psychiatry. 2000 Mar;57(3):249-58
6143669 - Eur J Clin Pharmacol. 1984;26(1):29-32
165915 - Clin Endocrinol (Oxf). 1975 Mar;4(2):191-8
14735295 - Psychopharmacology (Berl). 2004 Jul;174(3):414-20
8179790 - Neuropsychopharmacology. 1994 Feb;10(1):1-7
9829289 - Prog Neuropsychopharmacol Biol Psychiatry. 1998 Oct;22(7):1077-85
11763004 - J Clin Psychopharmacol. 2001 Dec;21(6):575-82
8387773 - Baillieres Clin Endocrinol Metab. 1993 Apr;7(2):355-92
1273208 - Psychopharmacologia. 1976 May 28;47(2):135-40
14706419 - Biol Psychiatry. 2004 Jan 1;55(1):1-9
6093182 - Psychopharmacology (Berl). 1984;84(1):66-70
7831445 - Psychopharmacology (Berl). 1993;112(1 Suppl):S90-4
12042192 - Am J Psychiatry. 2002 Jun;159(6):1018-28
1259521 - Arch Gen Psychiatry. 1976 Mar;33(3):279-86
1676524 - Psychopharmacology (Berl). 1991;103(4):443-8
8424312 - Acta Neurol Scand. 1993 Jan;87(1):52-5
11461709 - J Psychiatr Res. 2001 May-Jun;35(3):127-45
11738537 - Schizophr Res. 2002 Jan 15;53(3):239-48
11137052 - Biol Psychiatry. 2000 Dec 15;48(12):1121-32
11149386 - Can J Physiol Pharmacol. 2000 Dec;78(12):967-83
10839333 - Arch Gen Psychiatry. 2000 Jun;57(6):553-9
8588059 - Prog Neuropsychopharmacol Biol Psychiatry. 1995 Jul;19(4):603-14
12202292 - Am J Psychiatry. 2002 Sep;159(9):1608-9
11141696 - Pituitary. 2000 Oct;3(2):55-9
7897617 - J Psychiatr Res. 1994 Sep-Oct;28(5):461-73
4001434 - Prog Neuropsychopharmacol Biol Psychiatry. 1985;9(2):193-8
10451911 - Psychoneuroendocrinology. 1999 Oct;24(7):769-84
23087 - Arch Gen Psychiatry. 1978 Jan;35(1):108-16
14609883 - Arch Gen Psychiatry. 2003 Nov;60(11):1079-88
12552362 - Psychopharmacology (Berl). 2003 Mar;166(3):271-5
1754635 - Psychiatry Res. 1991 Sep;38(3):227-36
8690831 - J Clin Psychopharmacol. 1996 Apr;16(2):158-69
171278 - J Clin Endocrinol Metab. 1975 Nov;41(5):981-4
6527743 - Neuropharmacology. 1984 Dec;23(12A):1389-94
11132243 - Life Sci. 2000 Nov 24;68(1):29-39
11772702 - Am J Psychiatry. 2002 Jan;159(1):133-5
11136647 - Am J Psychiatry. 2001 Jan;158(1):131-4
2832287 - Horm Metab Res Suppl. 1987;16:36-8
8408451 - J Clin Endocrinol Metab. 1993 Oct;77(4):1033-40
7756102 - Br J Clin Pharmacol. 1995 Jan;39(1):7-14
12478881 - World J Biol Psychiatry. 2002 Jul;3(3):156-61
9442547 - Pharmacopsychiatry. 1997 Nov;30(6):250-5
2869509 - Pharmacol Rev. 1985 Sep;37(3):249-332
6239300 - Psychopharmacology (Berl). 1984;84(2):200-4
2682729 - Psychopharmacology (Berl). 1989;99 Suppl:S18-27
12107618 - Psychopharmacology (Berl). 2002 Jun;162(1):55-62
14744169 - J Clin Psychiatry. 2004 Jan;65(1):57-61
10625122 - Eur Neuropsychopharmacol. 1999 Dec;9(6):533-6
10647089 - Eur Neuropsychopharmacol. 1999 Dec;10(1):1-4
7659771 - Psychopharmacology (Berl). 1995 May;119(2):231-8
9442548 - Pharmacopsychiatry. 1997 Nov;30(6):256-62
12387684 - Expert Opin Pharmacother. 2002 Oct;3(10):1381-91
10511017 - Psychosom Med. 1999 Sep-Oct;61(5):698-711
2942747 - Life Sci. 1986 Jul 28;39(4):373-81
11027914 - Neuropsychopharmacology. 2000 Nov;23(5):477-501
9253318 - J Clin Endocrinol Metab. 1997 Aug;82(8):2458-65
12921492 - CNS Drugs. 2003;17(11):793-823
422303 - Int J Clin Pharmacol Biopharm. 1979 Feb;17(2):64-7
12611781 - Br J Psychiatry. 2003 Mar;182:199-204
6309434 - Clin Endocrinol (Oxf). 1983 Aug;19(2):239-45
3031718 - Psychoneuroendocrinology. 1986;11(4):475-89
9265916 - J Clin Psychiatry. 1997;58 Suppl 10:45-9
8085135 - Schizophr Bull. 1994;20(2):327-38
12363392 - Schizophr Res. 2002 Nov 1;58(1):69-74
References_xml – volume: 3
  start-page: 55
  year: 2000
  ident: 279_CR57
  publication-title: Pituitary
  doi: 10.1023/A:1009986822146
– volume: 37
  start-page: 249
  year: 1985
  ident: 279_CR59
  publication-title: Pharmacol Rev
– volume: 112
  start-page: S90
  year: 1993
  ident: 279_CR32
  publication-title: Psychopharmacology (Berl)
  doi: 10.1007/BF02245012
– volume: 53
  start-page: 239
  year: 2002
  ident: 279_CR61
  publication-title: Schizophr Res
  doi: 10.1016/S0920-9964(01)00268-7
– volume: 35
  start-page: 108
  year: 1978
  ident: 279_CR24
  publication-title: Arch Gen Psychiatry
  doi: 10.1001/archpsyc.1978.01770250110011
– ident: 279_CR71
– volume: 20
  start-page: 327
  year: 1994
  ident: 279_CR26
  publication-title: Schizophr Bull
  doi: 10.1093/schbul/20.2.327
– volume: 33
  start-page: 279
  year: 1976
  ident: 279_CR42
  publication-title: Arch Gen Psychiatry
  doi: 10.1001/archpsyc.1976.01770030003001
– volume: 158
  start-page: 131
  year: 2001
  ident: 279_CR55
  publication-title: Am J Psychiatry
  doi: 10.1176/appi.ajp.158.1.131
– volume: 60
  start-page: 1079
  year: 2003
  ident: 279_CR58
  publication-title: Arch Gen Psychiatry
  doi: 10.1001/archpsyc.60.11.1079
– volume: 65
  start-page: 57
  year: 2004
  ident: 279_CR62
  publication-title: J Clin Psychiatry
  doi: 10.4088/JCP.v65n0109
– volume: 84
  start-page: 200
  year: 1984
  ident: 279_CR47
  publication-title: Psychopharmacology (Berl)
  doi: 10.1007/BF00427446
– volume: 99
  start-page: S18
  issue: Suppl
  year: 1989
  ident: 279_CR41
  publication-title: Psychopharmacology (Berl)
  doi: 10.1007/BF00442554
– volume: 39
  start-page: 373
  year: 1986
  ident: 279_CR44
  publication-title: Life Sci
  doi: 10.1016/0024-3205(86)90656-9
– volume: 23
  start-page: 477
  year: 2000
  ident: 279_CR29
  publication-title: Neuropsychopharmacology
  doi: 10.1016/S0893-133X(00)00159-7
– volume: 47
  start-page: 135
  year: 1976
  ident: 279_CR50
  publication-title: Psychopharmacologia
  doi: 10.1007/BF00735811
– volume: 38
  start-page: 227
  year: 1991
  ident: 279_CR54
  publication-title: Psychiatry Res
  doi: 10.1016/0165-1781(91)90013-F
– volume: 16
  start-page: 158
  year: 1996
  ident: 279_CR13
  publication-title: J Clin Psychopharmacol
  doi: 10.1097/00004714-199604000-00008
– volume: 24
  start-page: 769
  year: 1999
  ident: 279_CR36
  publication-title: Psychoneuroendocrinology
  doi: 10.1016/S0306-4530(99)00029-3
– volume: 77
  start-page: 1033
  year: 1993
  ident: 279_CR45
  publication-title: J Clin Endocrinol Metab
– volume: 84
  start-page: 66
  year: 1984
  ident: 279_CR34
  publication-title: Psychopharmacology (Berl)
  doi: 10.1007/BF00432027
– volume: 166
  start-page: 271
  year: 2003
  ident: 279_CR52
  publication-title: Psychopharmacology (Berl)
  doi: 10.1007/s00213-002-1356-z
– volume: 57
  start-page: 553
  year: 2000
  ident: 279_CR33
  publication-title: Arch Gen Psychiatry
  doi: 10.1001/archpsyc.57.6.553
– volume: 87
  start-page: 52
  year: 1993
  ident: 279_CR40
  publication-title: Acta Neurol Scand
  doi: 10.1111/j.1600-0404.1993.tb04075.x
– volume: 68
  start-page: 29
  year: 2000
  ident: 279_CR49
  publication-title: Life Sci
  doi: 10.1016/S0024-3205(00)00911-5
– volume: 159
  start-page: 133
  year: 2002
  ident: 279_CR60
  publication-title: Am J Psychiatry
  doi: 10.1176/appi.ajp.159.1.133
– volume: 32
  start-page: 107
  year: 1996
  ident: 279_CR25
  publication-title: Psychopharmacol Bull
– start-page: 107
  volume-title: Psychoneuroendocrinology. The Scientific basis of clinical practice
  year: 2003
  ident: 279_CR30
  doi: 10.1176/appi.books.9798894550442.lg05
– volume: 3
  start-page: 1381
  year: 2002
  ident: 279_CR23
  publication-title: Expert Opin Pharmacother
  doi: 10.1517/14656566.3.10.1381
– volume: 41
  start-page: 981
  year: 1975
  ident: 279_CR18
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jcem-41-5-981
– volume: 58
  start-page: 69
  year: 2002
  ident: 279_CR56
  publication-title: Schizophr Res
  doi: 10.1016/S0920-9964(01)00367-X
– volume: 9
  start-page: 193
  year: 1985
  ident: 279_CR65
  publication-title: Prog Neuropsychopharmacol Biol Psychiatry
  doi: 10.1016/0278-5846(85)90082-X
– volume: 19
  start-page: 603
  year: 1995
  ident: 279_CR28
  publication-title: Prog Neuro-Psychopharmacol Biol Psychiatry
  doi: 10.1016/0278-5846(95)00105-5
– volume: 119
  start-page: 231
  year: 1995
  ident: 279_CR67
  publication-title: Psychopharmacology (Berl)
  doi: 10.1007/BF02246165
– volume: 39
  start-page: 7
  year: 1995
  ident: 279_CR20
  publication-title: Br J Clin Pharmacol
  doi: 10.1111/j.1365-2125.1995.tb04403.x
– volume: 21
  start-page: 575
  year: 2001
  ident: 279_CR51
  publication-title: J Clin Psychopharmacol
  doi: 10.1097/00004714-200112000-00006
– volume: 26
  start-page: 29
  year: 1984
  ident: 279_CR10
  publication-title: Eur J Clin Pharmacol
  doi: 10.1007/BF00546704
– volume: 103
  start-page: 443
  year: 1991
  ident: 279_CR63
  publication-title: Psychopharmacology (Berl)
  doi: 10.1007/BF02244242
– start-page: 284
  volume-title: American psychiatric association 157th annual meeting
  year: 2004
  ident: 279_CR16
– volume: 22
  start-page: 1077
  year: 1998
  ident: 279_CR27
  publication-title: Prog Neuro-Psychopharmacol Biol Psychiatry
  doi: 10.1016/S0278-5846(98)00064-5
– volume: 48
  start-page: 1121
  year: 2000
  ident: 279_CR64
  publication-title: Biol Psychiatry
  doi: 10.1016/S0006-3223(00)01052-0
– volume: 7
  start-page: 355
  year: 1993
  ident: 279_CR3
  publication-title: Clin Endocrinol Metab
– volume: 78
  start-page: 967
  year: 2000
  ident: 279_CR19
  publication-title: Can J Physiol Pharmacol
  doi: 10.1139/y00-098
– volume: 17
  start-page: 793
  year: 2003
  ident: 279_CR43
  publication-title: CNS Drugs
  doi: 10.2165/00023210-200317110-00003
– volume: 4
  start-page: 191
  year: 1975
  ident: 279_CR69
  publication-title: Clin Endocrinol (Oxf)
  doi: 10.1111/j.1365-2265.1975.tb01526.x
– volume: 10
  start-page: 1
  year: 1994
  ident: 279_CR14
  publication-title: Neuropsychopharmacology
  doi: 10.1038/npp.1994.1
– volume: 170
  start-page: 463
  year: 1982
  ident: 279_CR22
  publication-title: J Nerv Ment Dis
  doi: 10.1097/00005053-198208000-00004
– volume: 61
  start-page: 698
  year: 1999
  ident: 279_CR70
  publication-title: Psychosom Med
  doi: 10.1097/00006842-199909000-00011
– volume: 57
  start-page: 249
  year: 2000
  ident: 279_CR48
  publication-title: Arch Gen Psychiatry
  doi: 10.1001/archpsyc.57.3.249
– volume: 17
  start-page: 64
  year: 1979
  ident: 279_CR31
  publication-title: Int J Clin Pharmacol Biopharm
– volume: 82
  start-page: 2458
  year: 1997
  ident: 279_CR53
  publication-title: J Clin Endocrinol Metab
– volume: 3
  start-page: 156
  year: 2002
  ident: 279_CR38
  publication-title: World J Biol Psychiatry
  doi: 10.3109/15622970209150617
– volume: 182
  start-page: 199
  year: 2003
  ident: 279_CR68
  publication-title: Br J Psychiatry
  doi: 10.1192/bjp.182.3.199
– volume: 16
  start-page: 36
  year: 1987
  ident: 279_CR6
  publication-title: Horm Metab Res Suppl
– volume: 30
  start-page: 256
  year: 1997
  ident: 279_CR9
  publication-title: Pharmacopsychiatry
  doi: 10.1055/s-2007-979503
– volume: 28
  start-page: 461
  year: 1994
  ident: 279_CR66
  publication-title: J Psychiatr Res
  doi: 10.1016/0022-3956(94)90004-3
– volume: 58
  start-page: 45
  issue: Suppl 10
  year: 1997
  ident: 279_CR46
  publication-title: J Clin Psychiatry
– volume: 63
  start-page: 32
  year: 2002
  ident: 279_CR2
  publication-title: J Clin Psychiatry
– volume: 55
  start-page: 1
  year: 2004
  ident: 279_CR15
  publication-title: Biol Psychiatry
  doi: 10.1016/S0006-3223(03)00473-6
– volume: 174
  start-page: 414
  year: 2004
  ident: 279_CR17
  publication-title: Psychopharmacology (Berl)
– volume: 10
  start-page: 1
  year: 1999
  ident: 279_CR7
  publication-title: Eur Neuropsychopharmacol
  doi: 10.1016/S0924-977X(99)00017-6
– volume: 35
  start-page: 127
  year: 2001
  ident: 279_CR11
  publication-title: J Psychiatr Res
  doi: 10.1016/S0022-3956(01)00018-8
– volume: 23
  start-page: 1389
  year: 1984
  ident: 279_CR21
  publication-title: Neuropharmacology
  doi: 10.1016/0028-3908(84)90078-9
– volume: 162
  start-page: 55
  year: 2002
  ident: 279_CR1
  publication-title: Psychopharmacology (Berl)
  doi: 10.1007/s00213-002-1057-7
– volume: 159
  start-page: 1018
  year: 2002
  ident: 279_CR12
  publication-title: Am J Psychiatry
  doi: 10.1176/appi.ajp.159.6.1018
– volume: 9
  start-page: 533
  year: 1999
  ident: 279_CR39
  publication-title: Eur Neuropsychopharmacol
  doi: 10.1016/S0924-977X(99)00040-1
– volume: 11
  start-page: 475
  year: 1986
  ident: 279_CR35
  publication-title: Psychoneuroendocrinology
  doi: 10.1016/0306-4530(86)90008-9
– volume: 30
  start-page: 250
  year: 1997
  ident: 279_CR8
  publication-title: Pharmacopsychiatry
  doi: 10.1055/s-2007-979502
– volume: 19
  start-page: 239
  year: 1983
  ident: 279_CR5
  publication-title: Clin Endocrinol (Oxf)
  doi: 10.1111/j.1365-2265.1983.tb02986.x
– volume: 266
  start-page: 639
  year: 1977
  ident: 279_CR37
  publication-title: Nature
  doi: 10.1038/266639a0
– volume: 159
  start-page: 1608
  year: 2002
  ident: 279_CR4
  publication-title: Am J Psychiatry
  doi: 10.1176/appi.ajp.159.9.1608
– reference: 2942747 - Life Sci. 1986 Jul 28;39(4):373-81
– reference: 10839333 - Arch Gen Psychiatry. 2000 Jun;57(6):553-9
– reference: 8387773 - Baillieres Clin Endocrinol Metab. 1993 Apr;7(2):355-92
– reference: 8588059 - Prog Neuropsychopharmacol Biol Psychiatry. 1995 Jul;19(4):603-14
– reference: 9442547 - Pharmacopsychiatry. 1997 Nov;30(6):250-5
– reference: 7756102 - Br J Clin Pharmacol. 1995 Jan;39(1):7-14
– reference: 4001434 - Prog Neuropsychopharmacol Biol Psychiatry. 1985;9(2):193-8
– reference: 8424312 - Acta Neurol Scand. 1993 Jan;87(1):52-5
– reference: 3031718 - Psychoneuroendocrinology. 1986;11(4):475-89
– reference: 171278 - J Clin Endocrinol Metab. 1975 Nov;41(5):981-4
– reference: 2869509 - Pharmacol Rev. 1985 Sep;37(3):249-332
– reference: 6309434 - Clin Endocrinol (Oxf). 1983 Aug;19(2):239-45
– reference: 14735295 - Psychopharmacology (Berl). 2004 Jul;174(3):414-20
– reference: 11738537 - Schizophr Res. 2002 Jan 15;53(3):239-48
– reference: 11136647 - Am J Psychiatry. 2001 Jan;158(1):131-4
– reference: 10711911 - Arch Gen Psychiatry. 2000 Mar;57(3):249-58
– reference: 10511017 - Psychosom Med. 1999 Sep-Oct;61(5):698-711
– reference: 7831445 - Psychopharmacology (Berl). 1993;112(1 Suppl):S90-4
– reference: 14744169 - J Clin Psychiatry. 2004 Jan;65(1):57-61
– reference: 12387684 - Expert Opin Pharmacother. 2002 Oct;3(10):1381-91
– reference: 6239300 - Psychopharmacology (Berl). 1984;84(2):200-4
– reference: 2682729 - Psychopharmacology (Berl). 1989;99 Suppl:S18-27
– reference: 1676524 - Psychopharmacology (Berl). 1991;103(4):443-8
– reference: 422303 - Int J Clin Pharmacol Biopharm. 1979 Feb;17(2):64-7
– reference: 14609883 - Arch Gen Psychiatry. 2003 Nov;60(11):1079-88
– reference: 11772702 - Am J Psychiatry. 2002 Jan;159(1):133-5
– reference: 11137052 - Biol Psychiatry. 2000 Dec 15;48(12):1121-32
– reference: 12562145 - J Clin Psychiatry. 2002;63 Suppl 13:32-8
– reference: 23087 - Arch Gen Psychiatry. 1978 Jan;35(1):108-16
– reference: 12202292 - Am J Psychiatry. 2002 Sep;159(9):1608-9
– reference: 7897617 - J Psychiatr Res. 1994 Sep-Oct;28(5):461-73
– reference: 9253318 - J Clin Endocrinol Metab. 1997 Aug;82(8):2458-65
– reference: 11149386 - Can J Physiol Pharmacol. 2000 Dec;78(12):967-83
– reference: 12042192 - Am J Psychiatry. 2002 Jun;159(6):1018-28
– reference: 8408451 - J Clin Endocrinol Metab. 1993 Oct;77(4):1033-40
– reference: 6527743 - Neuropharmacology. 1984 Dec;23(12A):1389-94
– reference: 1754635 - Psychiatry Res. 1991 Sep;38(3):227-36
– reference: 11141696 - Pituitary. 2000 Oct;3(2):55-9
– reference: 14706419 - Biol Psychiatry. 2004 Jan 1;55(1):1-9
– reference: 12478881 - World J Biol Psychiatry. 2002 Jul;3(3):156-61
– reference: 11763004 - J Clin Psychopharmacol. 2001 Dec;21(6):575-82
– reference: 11461709 - J Psychiatr Res. 2001 May-Jun;35(3):127-45
– reference: 11132243 - Life Sci. 2000 Nov 24;68(1):29-39
– reference: 12363392 - Schizophr Res. 2002 Nov 1;58(1):69-74
– reference: 6143669 - Eur J Clin Pharmacol. 1984;26(1):29-32
– reference: 12552362 - Psychopharmacology (Berl). 2003 Mar;166(3):271-5
– reference: 8085135 - Schizophr Bull. 1994;20(2):327-38
– reference: 6124580 - J Nerv Ment Dis. 1982 Aug;170(8):463-7
– reference: 12921492 - CNS Drugs. 2003;17(11):793-823
– reference: 1273208 - Psychopharmacologia. 1976 May 28;47(2):135-40
– reference: 9442548 - Pharmacopsychiatry. 1997 Nov;30(6):256-62
– reference: 165915 - Clin Endocrinol (Oxf). 1975 Mar;4(2):191-8
– reference: 1259521 - Arch Gen Psychiatry. 1976 Mar;33(3):279-86
– reference: 10647089 - Eur Neuropsychopharmacol. 1999 Dec;10(1):1-4
– reference: 8179790 - Neuropsychopharmacology. 1994 Feb;10(1):1-7
– reference: 10625122 - Eur Neuropsychopharmacol. 1999 Dec;9(6):533-6
– reference: 11027914 - Neuropsychopharmacology. 2000 Nov;23(5):477-501
– reference: 7659771 - Psychopharmacology (Berl). 1995 May;119(2):231-8
– reference: 12107618 - Psychopharmacology (Berl). 2002 Jun;162(1):55-62
– reference: 12611781 - Br J Psychiatry. 2003 Mar;182:199-204
– reference: 193037 - Nature. 1977 Apr 14;266(5603):639-40
– reference: 9829289 - Prog Neuropsychopharmacol Biol Psychiatry. 1998 Oct;22(7):1077-85
– reference: 9265916 - J Clin Psychiatry. 1997;58 Suppl 10:45-9
– reference: 8690831 - J Clin Psychopharmacol. 1996 Apr;16(2):158-69
– reference: 10451911 - Psychoneuroendocrinology. 1999 Oct;24(7):769-84
– reference: 2832287 - Horm Metab Res Suppl. 1987;16:36-8
– reference: 8927658 - Psychopharmacol Bull. 1996;32(1):107-10
– reference: 6093182 - Psychopharmacology (Berl). 1984;84(1):66-70
SSID ssj0000484
ssj0068394
Score 2.2076533
Snippet Increased activity of the hypothalamic-pituitary-adrenal (HPA) axis is an important aspect of the pathophysiology of major depression and schizophrenia....
Rationale: Increased activity of the hypothalamic-pituitary-adrenal (HPA) axis is an important aspect of the pathophysiology of major depression and...
SourceID proquest
pubmed
pascalfrancis
crossref
SourceType Aggregation Database
Index Database
Enrichment Source
StartPage 11
SubjectTerms Adrenocorticotropic Hormone - blood
Adult
Antipsychotic Agents - pharmacology
Antipsychotics
Benzodiazepines - pharmacology
Biological and medical sciences
Cross-Over Studies
Dibenzothiazepines - pharmacology
Double-Blind Method
Haloperidol - pharmacology
Humans
Hydrocortisone - blood
Hypothalamo-Hypophyseal System - drug effects
Male
Medical sciences
Neuropharmacology
Pharmacology. Drug treatments
Pituitary-Adrenal System - drug effects
Prolactin - blood
Psycholeptics: tranquillizer, neuroleptic
Psychology. Psychoanalysis. Psychiatry
Psychopharmacology
Quetiapine Fumarate
Title The atypical antipsychotics olanzapine and quetiapine, but not haloperidol, reduce ACTH and cortisol secretion in healthy subjects
URI https://www.ncbi.nlm.nih.gov/pubmed/16432682
https://www.proquest.com/docview/218960963
https://www.proquest.com/docview/19284570
https://www.proquest.com/docview/20607353
https://www.proquest.com/docview/67688578
Volume 185
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9swED-2FsagjK378rplehh9GDHzl2T5aSSlIQwawkghb0aSZRYItlc70PRxf_nubCehD82TEZKM0El3P0l3vwP4JrPcj0NEbrlRxo0SqVyVR56bRTpXPNTatjyzNzMxvY1-Lfmy982pe7fKnU5sFXVWGroj_4GmiMjRRPiz-utS0ih6XO0zaDyHU2IuI4-ueBkfFHFEMZhdQSAQ6BiZQ4on43L3wum1hKIB5TggN7YgTtz7RzbqrFI1Tlfe5bl4Goi2BmnyGl71SJKNOtG_gWe2OIcXN_1b-TlczjtW6u2QLQ5BVvWQXbL5ga96-xb-YTVTzbYieTGc6VUfmoWtGZ58iwdV4R-xJmM4JFQJVBwyvWlYUTbsj1qXxJecleshuyMqWMtGV4tp2wEPt80K1zerCZ_SKmCrgnXRl1tWbzTdA9Xv4HZyvbiaun1qBtdEvmxc3wqTxHlm0LglBifa8CzJEm24tcrXNiRmPYSCgdCxlqFUylMmVAi-OB7lEx2-h5OiLOxHYCaySYSm2giliAlH-cJYTyaWa6V9ETjg7YSRmp63nNJnrNM943IrvxTll5L80nsHvu-7VB1px7HGg0cSPvSIeUwpUR242Ik87Td4ne6XowNf97W4M-m5RRW23NQpYmcZ8dh7ukXgCdSw_Mg_BJ4GJSpVBz50a-0wOoSSgZDBp6Oju4CX3Z0ROc19hpPmbmO_IIpq9KDdKwM4HU3G4xl-x9ez-e__yGIfWQ
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VrQRICEF5hULrA_SANiJPJzkgVEqrLe2uVmgr9RZsxxErrZLQZEXDkf_Df2Qmj1310L31GDm2LH3j8Te25xuAd2GS2oGLzC1VQpleFApTpJ5lJp5Mhe9KqRud2fGEjy68b5f-5Rb863Nh6Fll7xMbR53kis7IP-JWROJo3P1c_DKpaBRdrvYVNFqrONP1b4zYyk-nXxHe945zcjw7GpldUQFTeXZYmbbmKgrSRKFbjhTar_KTKImk8rUWttQuacIhiXG4DGTohkJYQrkCaYOPQWgkXRz3Hmx7LkYyA9j-cjyZfl-7fo-yPtsPjtSj1YB2KYPND_s7VauRMHWoqgI9nHOCyLy-sSs-KkSJAKVtZY3bqW-zBZ48gccdd2WHrbE9hS2d7cD9cXc7vwMH01YHux6y2TqtqxyyAzZdK2TXz-AvNjNR1QVZCENs510yGP7NMNbO_ogCR8SWhOGU0AnR55DJZcWyvGI_xSInheYkXwzZFYnPanZ4NBs1HTCcrua4olhJjJjsjs0z1uZ71qxcSjp5Kp_DxZ3g9gIGWZ7pV8CUpyMPyYHiQpD2jrC50lYYaV8KaXPHAKsHI1adUjoV7FjEK43nBr8Y8YsJv_jagA-rLkUrE7Lp570bCK97BH5ARVgN2O0hjzuXUsarBWDA_qoVfQFd8IhM58syRrYeen5g3f6HY3H06f6GMTjGnyG6cQNetra2nh2SV4eHzuuNs9uHB6PZ-Dw-P52c7cLD9sSKnuy9gUF1tdRvkcNVcq9bOQx-3PVi_Q_Vx1se
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VIlVICEGBEgqtD9AD2qh52UkOCFUtqy2l1R620t6C7ThipVUSmqzocuRf8e-YyWNXPXRvPVp-yNI8_I3t-QbgQ5Rmbugjcsu01HYQR9KWWeDYaaAyyX2lTMMze3klRtfBtymfbsG_PheGvlX2PrFx1Gmh6Y78GI8iIkcT_nHW_YoYnw2_lL9sKiBFD619NY1WQy7M8jdGb9Xn8zMU9UfPG36dnI7srsCArQM3qm3XCB2HWarRRccadVnzNE5jpbkx0lXGJ344BDSeUKGK_EhKR2pfIoTgGJDGysd1H8Hj0OcumVg4DdeHQED5n21DIAhp2aB9ymXjUf-66jRkph7VV6AvdF4Y27d3zsenpaxQVFlbY-N-ENwchsPn8KxDseykVbsXsGXyXdi57N7pd-Fo3DJiLwdssk7wqgbsiI3XXNnLl_AXu5mslyXpCkMpz7q0MBzNMOrO_8gSV8SelOGW0B1Rc8DUomZ5UbOfcl4QV3NazAfshmhoDTs5nYyaCRhY1zO0LVYRNiYNZLOctZmfS1YtFN1BVa_g-kGk9hq28yI3b4DpwMQBwgQtpCQWHukKbZwoNlxJ5QrPAqcXRqI7znQq3TFPVmzPjfwSlF9C8ktuLfi0mlK2hCGbBh_ckfB6RshDKsdqwX4v8qRzLlWyMgULDle96BXoqUfmplhUCeL2KOChc_8IzxHo3fmGNQRGohE6dAv2Wl1b7w5hrCci7-3G3R3CDppo8v386mIfnrRXV_R37x1s1zcL8x7BXK0OGrNh8OOh7fQ_FAZd7g
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+atypical+antipsychotics+olanzapine+and+quetiapine%2C+but+not+haloperidol%2C+reduce+ACTH+and+cortisol+secretion+in+healthy+subjects&rft.jtitle=Psychopharmacology&rft.au=Cohrs%2C+Stefan&rft.au=R%C3%B6her%2C+Cornelia&rft.au=Jordan%2C+Wolfgang&rft.au=Meier%2C+Andreas&rft.date=2006-03-01&rft.issn=0033-3158&rft.volume=185&rft.issue=1&rft.spage=11&rft_id=info:doi/10.1007%2Fs00213-005-0279-x&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0033-3158&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0033-3158&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0033-3158&client=summon